FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / BMC Vet Res / Probing Wnt pathway and functional signal in equine melanocy...
BMC veterinary research2025; 21(1); 509; doi: 10.1186/s12917-025-04956-w

Probing Wnt pathway and functional signal in equine melanocytic neoplasms through quantitative proteomics and immunohistochemistry.

Abstract: Equine melanocytic neoplasm (EMN) is a skin tumor commonly observed in grey horses. Limited research has yet to investigate proteomic profiles of EMN, particularly in the early stages and their expression patterns. This study, therefore, aimed to identify signature proteins from tissue biopsies to distinguish early EMN, severe EMN, and normal groups. Results: Using proteomic analysis of 19 tissue samples (normal: n = 6, early EMN: n = 7, severe EMN: n = 6) through LC-MS/MS, 12,310 proteins were identified. Differentially expressed proteins (DEPs) and functional interaction analysis revealed significant overexpression of Wnt signature proteins, e.g., canonical (Wnt2B) and non-canonical (Wnt5B) Wnt signaling in early EMN stages. Immunohistochemical staining (IHC) towards immunolocalizing Wnt signature protein, particularly the Wnt2B functional signal, further verified its higher expression in early EMN compared to other groups. Conclusions: These findings suggest that the Wnt pathway and functional insight are key mediators in signal transduction during early EMN, offering potential markers for initial stage detection. This study enhances the understanding of EMN mechanisms and the role of Wnt proteins, with implications for developing future diagnostic and therapeutic strategies.
© 2025. The Author(s).
Get Full Text
Publication Date: 2025-08-07 PubMed ID: 40775356PubMed Central: PMC12329947DOI: 10.1186/s12917-025-04956-wGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research article investigates the underlying proteins that play a role in equine melanocytic neoplasm (EMN), a prevalent skin tumor in grey horses. The researchers discovered a significant overexpression of Wnt signature proteins in the early stages of EMN, suggesting they could serve as markers for detection.

Study Objective

  • The main objective of the study was to analyze the proteomic profiles in tissue samples of EMN, with a specific focus on distinguishing the early stages of EMN from severe EMN and normal tissue categories.

Methodology

  • 19 tissue samples were collected, including six normal samples, seven early EMN samples, and six severe EMN samples.
  • These samples were then subjected to proteomic analysis using a method called Liquid chromatography–mass spectrometry (LC-MS/MS).
  • Through this process, they identified more than 12,000 proteins.
  • The researchers then looked for differentially expressed proteins (DEPs) and analyzed the functional interactions of these proteins.
  • Further verification of these findings was carried out using Immunohistochemical staining (IHC) to identify the localization of Wnt signature proteins, particularly Wnt2B.

Results

  • The analysis revealed a significant overexpression of Wnt signature proteins, including Wnt2B (canonical) and Wnt5B (non-canonical), in the early stages of EMN.
  • This overexpression was further verified by IHC, which confirmed a higher presence of Wnt2B in early EMN samples compared to the other groups.

Conclusions

  • The study confirms the central role of Wnt proteins, particularly Wnt2B, in the early stages of EMN signal transduction.
  • The findings provide a better understanding of the mechanisms behind EMN and the role of Wnt proteins, potentially making them markers for the detection of initial stage EMN.
  • The results also have implications for the development of future diagnostic and therapeutic strategies for EMN.

Cite This Article

APA
Tesena P, Vinijkumthorn R, Kingkaw A, Yanyongsirikarn P, Phasuk K, Ploypetch S, Phaonakrop N, Roytrakul S, Vongsangnak W, Prapaiwan N. (2025). Probing Wnt pathway and functional signal in equine melanocytic neoplasms through quantitative proteomics and immunohistochemistry. BMC Vet Res, 21(1), 509. https://doi.org/10.1186/s12917-025-04956-w

Publication

BMC veterinary research
ISSN: 1746-6148
NlmUniqueID: 101249759
Country: England
Language: English
Volume: 21
Issue: 1
Pages: 509
PII: 509

Researcher Affiliations

Tesena, Parichart
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Vinijkumthorn, Ruethaiwan
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Kingkaw, Amornthep
  • Faculty of Science, Interdisciplinary Graduate Program in Bioscience, Kasetsart University, Bangkok, 10900, Thailand.
Yanyongsirikarn, Petchpailin
  • Faculty of Veterinary Science, Equine Clinic, Prasuarthon Small Animal Hospital, Mahidol University, Nakhon Pathom, 73170, Thailand.
Phasuk, Khajornpol
  • Veterinary Medicine Disposal and Animal Husbandry, Sub-Division Patrol Special Operation Division, Mounted Police Sub-Division, Bangkok, 10150, Thailand.
Ploypetch, Sekkarin
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand.
Phaonakrop, Narumon
  • Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, 12120, Thailand.
Roytrakul, Sittiruk
  • Functional Proteomics Technology Laboratory, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency, Pathum Thani, 12120, Thailand.
Vongsangnak, Wanwipa
  • Department of Zoology, Faculty of Science, Kasetsart University, Bangkok, 10900, Thailand. wanwipa.v@ku.ac.th.
  • Omics Center for Agriculture, Bioresources, Food, and Health, Kasetsart University (OmiKU), Bangkok, 10900, Thailand. wanwipa.v@ku.ac.th.
Prapaiwan, Nawarus
  • Department of Clinical Science and Public Health, Faculty of Veterinary Science, Mahidol University, Nakhon Pathom, 73170, Thailand. nawarus.pra@mahidol.ac.th.

MeSH Terms

  • Animals
  • Horses
  • Horse Diseases / metabolism
  • Horse Diseases / pathology
  • Proteomics
  • Wnt Signaling Pathway / physiology
  • Immunohistochemistry / veterinary
  • Melanoma / veterinary
  • Melanoma / metabolism
  • Melanoma / pathology
  • Skin Neoplasms / veterinary
  • Skin Neoplasms / metabolism
  • Skin Neoplasms / pathology
  • Male
  • Female
  • Tandem Mass Spectrometry / veterinary

Conflict of Interest Statement

Declarations. Ethics approval and consent to participate: All procedures involving animals were done in compliance with animal welfare and ethical guidelines provided by The Faculty of Veterinary Science, which approved the experimental protocol; Mahidol University-Institute Animal Care and Use Committee (FVS-MU-IACUC) reviewed and approved the experiment under permission No. MUVS-2023–04-30; the horse owners signed an informed consent form. Consent for publication: Not applicable. Competing interest: The authors declare no competing interests.

References

This article includes 73 references
  1. Valentine BA. Equine melanocytic tumors: a retrospective study of 53 horses (1988 to 1991).. J Vet Intern Med 1995;9(5):291–7.
    pubmed: 8531173doi: 10.1111/j.1939-1676.1995.tb01087.xgoogle scholar: lookup
  2. Fleury C, Berard F, Leblond A, Faure C, Ganem N, Thomas L. The study of cutaneous melanomas in Camargue-type gray-skinned horses (2): epidemiological survey.. Pigment Cell Res 2000;13(1):47–51.
    pubmed: 10761996doi: 10.1034/j.1600-0749.2000.130109.xgoogle scholar: lookup
  3. Rieder S, Stricker CH, Joerg H, Dummer R, Stranzinger G. A comparative genetic approach for the investigation of ageing grey horse melanoma.. J Anim Breed Genet 2000;117(2):73–82.
    doi: 10.1111/j.1439-0388.2000x.00245.xgoogle scholar: lookup
  4. Curik I, Druml T, Seltenhammer M, Sundstrom E, Pielberg GR, Andersson L, Solkner J. Complex inheritance of melanoma and pigmentation of coat and skin in grey horses.. PLoS Genet 2013;9(2): e1003248.
    pmc: PMC3567150pubmed: 23408897doi: 10.1371/journal.pgen.1003248google scholar: lookup
  5. Rosengren Pielberg G, Golovko A, Sundstrom E, Curik I, Lennartsson J, Seltenhammer MH, Druml T, Binns M, Fitzsimmons C, Lindgren G. A cis-acting regulatory mutation causes premature hair graying and susceptibility to melanoma in the horse.. Nat Genet 2008;40(8):1004–9.
    pubmed: 18641652doi: 10.1038/ng.185google scholar: lookup
  6. Teixeira RB, Rendahl AK, Anderson SM, Mickelson JR, Sigler D, Buchanan BR, Coleman RJ, McCue ME. Coat color genotypes and risk and severity of melanoma in gray quarter horses.. J Vet Intern Med 2013;27(5):1201–8.
    pubmed: 23875712doi: 10.1111/jvim.12133google scholar: lookup
  7. Pimenta J, Prada J, Cotovio M. Equine melanocytic tumors: a narrative review.. Animals 2023;13(2): 247.
    pmc: PMC9855132pubmed: 36670786doi: 10.3390/ani13020247google scholar: lookup
  8. Smalley KS. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?. Int J Cancer 2003;104(5):527–32.
    pubmed: 12594806doi: 10.1002/ijc.10978google scholar: lookup
  9. Jiang L, Campagne C, Sundstrom E, Sousa P, Imran S, Seltenhammer M, Pielberg G, Olsson MJ, Egidy G, Andersson L. Constitutive activation of the ERK pathway in melanoma and skin melanocytes in Grey horses.. BMC Cancer 2014;14: 857.
    pmc: PMC4254013pubmed: 25413220doi: 10.1186/1471-2407-14-857google scholar: lookup
  10. Moore JS, Shaw C, Shaw E, Buechner-Maxwell V, Scarratt WK, Crisman M, Furr M, Robertson J. Melanoma in horses: current perspectives.. Equine Vet Educ 2013;25(3):144–51.
    doi: 10.1111/j.2042-3292.2011.00368.xgoogle scholar: lookup
  11. Seltenhammer MH, Simhofer H, Scherzer S, Zechner R, Curik I, Solkner J, Brandt SM, Jansen B, Pehamberger H, Eisenmenger E. Equine melanoma in a population of 296 grey Lipizzaner horses.. Equine Vet J 2003;35(2):153–7.
    pubmed: 12638791doi: 10.2746/042516403776114234google scholar: lookup
  12. Wong K, van der Weyden L, Schott CR, Foote A, Constantino-Casas F, Smith S, Dobson JM, Murchison EP, Wu H, Yeh I. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma.. Nat Commun 2019;10(1):353.
    pmc: PMC6341101pubmed: 30664638doi: 10.1038/s41467-018-08081-1google scholar: lookup
  13. MacGillivray KC, Sweeney RW, Del Piero F. Metastatic melanoma in horses.. J Vet Intern Med 2002;16(4):452–6.
    pubmed: 12141308doi: 10.1892/0891-6640(2002)016%3c0452:mmih%3e2.3.co;2google scholar: lookup
  14. Phillips JC, Lembcke LM. Equine melanocytic tumors.. Vet Clin North Am Equine Pract 2013;29(3):673–87.
    pubmed: 24267683doi: 10.1016/j.cveq.2013.08.008google scholar: lookup
  15. Johnson PJ. Dermatologic tumors (excluding sarcoids).. Vet Clin North Am Equine Pract 1998;14(3):625–58.
    pubmed: 9891728doi: 10.1016/s0749-0739(17)30190-6google scholar: lookup
  16. Ramos-Vara JA, Kiupel M, Baszler T, Bliven L, Brodersen B, Chelack B, Czub S, Del Piero F, Dial S, Ehrhart EJ. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories.. J Vet Diagn Invest 2008;20(4):393–413.
    pubmed: 18599844doi: 10.1177/104063870802000401google scholar: lookup
  17. Sheffield MV, Yee H, Dorvault CC, Weilbaecher KN, Eltoum IA, Siegal GP, Fisher DE, Chhieng DC. Comparison of five antibodies as markers in the diagnosis of melanoma in cytologic preparations.. Am J Clin Pathol 2002;118(6):930–6.
    pubmed: 12472287doi: 10.1309/ewk9-lupr-6bc5-1gxvgoogle scholar: lookup
  18. Morris LG, Wen YH, Nonaka D, DeLacure MD, Kutler DI, Huan Y, Wang BY. PNL2 melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck.. Head Neck 2008;30(6):771–5.
    pubmed: 18228523doi: 10.1002/hed.20785google scholar: lookup
  19. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma.. J Cutan Pathol 2008;35(5):433–44.
    pubmed: 18399807doi: 10.1111/j.1600-0560.2007.00891.xgoogle scholar: lookup
  20. Lilyquist J, White KAM, Lee RJ, Philips GK, Hughes CR, Torres SM. Quantitative analysis of immunohistochemistry in melanoma tumors.. Medicine (Baltimore) 2017;96(15): e6432.
    pmc: PMC5403070pubmed: 28403073doi: 10.1097/md.0000000000006432google scholar: lookup
  21. Seltenhammer MH, Heere-Ress E, Brandt S, Druml T, Jansen B, Pehamberger H, Niebauer GW. Comparative histopathology of grey-horse-melanoma and human malignant melanoma.. Pigment Cell Res 2004;17(6):674–81.
    pubmed: 15541026doi: 10.1111/j.1600-0749.2004.00192.xgoogle scholar: lookup
  22. Ramos-Vara JA, Webster JD, DuSold D, Miller MA. Immunohistochemical evaluation of the effects of paraffin section storage on biomarker stability.. Vet Pathol 2014;51(1):102–9.
    pubmed: 23435571doi: 10.1177/0300985813476067google scholar: lookup
  23. Vitzthum F, Behrens F, Anderson NL, Shaw JH. Proteomics: from basic research to diagnostic application. A review of requirements & needs.. J Proteome Res 2005;4(4):1086–97.
    pubmed: 16083257doi: 10.1021/pr050080bgoogle scholar: lookup
  24. Sabel MS, Liu Y, Lubman DM. Proteomics in melanoma biomarker discovery: great potential, many obstacles.. Int J Proteomics 2011;2011: 181890.
    pmc: PMC3195774pubmed: 22084682doi: 10.1155/2011/181890google scholar: lookup
  25. Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer.. Nat Rev Cancer 2003;3(4):267–75.
    pubmed: 12671665doi: 10.1038/nrc1043google scholar: lookup
  26. Tesena P, Kingkaw A, Vongsangnak W, Pitikarn S, Phaonakrop N, Roytrakul S, Kovitvadhi A. Preliminary study: Proteomic profiling uncovers potential proteins for biomonitoring equine melanocytic neoplasm.. Animals 2021;11(7): 1913.
    pmc: PMC8300200pubmed: 34199079doi: 10.3390/ani11071913google scholar: lookup
  27. Pellerin L, Carrie L, Dufau C, Nieto L, Segui B, Levade T, Riond J, Andrieu-Abadie N. Lipid metabolic reprogramming: role in melanoma progression and therapeutic perspectives.. Cancers (Basel) 2020;12(11): 3147.
    pmc: PMC7692067pubmed: 33121001doi: 10.3390/cancers12113147google scholar: lookup
  28. Tesena P, Kingkaw A, Phaonakrop N, Roytrakul S, Limudomporn P, Vongsangnak W, Kovitvadhi A. Faecal proteomics and functional analysis of equine melanocytic neoplasm in grey horses.. Vet Sci 2022;9(2):94.
    pmc: PMC8875177pubmed: 35202347doi: 10.3390/vetsci9020094google scholar: lookup
  29. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms.. Vet Pathol 2002;39(6):651–78.
    pubmed: 12450197doi: 10.1354/vp.39-6-651google scholar: lookup
  30. Desser H, Niebauer GW, Gebhart W. Polyamine and histamine contents in the blood of pigmented, depigmented and melanoma bearing Lipizzaner horses.. Zentralbl Veterinarmed A 1980;27(1):45–53.
    pubmed: 6774520doi: 10.1111/j.1439-0442.1980.tb01667.xgoogle scholar: lookup
  31. Clark-Price S, Mama K. Equine anesthesia and co-existing disease.. New Jersey: John Wiley & Sons; 2022.
  32. Horing M, Krautbauer S, Hiltl L, Babl V, Sigruener A, Burkhardt R, Liebisch G. Accurate lipid quantification of tissue homogenates requires suitable sample concentration, solvent composition, and homogenization procedure-a case study in murine liver.. Metabolites 2021;11(6): 365.
    pmc: PMC8228350pubmed: 34201055doi: 10.3390/metabo11060365google scholar: lookup
  33. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent.. J Biol Chem 1951;193(1):265–75.
    pubmed: 14907713doi: 10.1016/s0021-9258(19)52451-6google scholar: lookup
  34. Tyanova S, Temu T, Cox J. The maxquant computational platform for mass spectrometry-based shotgun proteomics.. Nat Protoc 2016;11(12):2301–19.
    pubmed: 27809316doi: 10.1038/nprot.2016.136google scholar: lookup
  35. Johansson C, Samskog J, Sundstrom L, Wadensten H, Bjorkesten L, Flensburg J. Differential expression analysis of proteins using a novel software for relative quantitation of LC-MS/MS data.. Proteomics 2006;6(16):4475–85.
    pubmed: 16858737doi: 10.1002/pmic.200500921google scholar: lookup
  36. Thorsell A, Portelius E, Blennow K, Westman-Brinkmalm A. Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experiment.. Rapid Commun Mass Spectrom 2007;21(5):771–8.
    pubmed: 17279600doi: 10.1002/rcm.2898google scholar: lookup
  37. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M. The KEGG resource for deciphering the genome.. Nucleic Acids Res 2004;32(Database issue):D277–280.
    pmc: PMC308797pubmed: 14681412doi: 10.1093/nar/gkh063google scholar: lookup
  38. Wang H, Penaloza T, Manea AJ, Gao XPFKP. More than phosphofructokinase.. Adv Cancer Res 2023;160:1–15.
    pmc: PMC12125951pubmed: 37704285doi: 10.1016/bs.acr.2023.03.001google scholar: lookup
  39. Khan GB, Qasim M, Rasul A, Ashfaq UA, Alnuqaydan AM. Identification of lignan compounds as new 6-phosphogluconate dehydrogenase inhibitors for lung cancer.. Metabolites 2022;13(1):34.
    pmc: PMC9864769pubmed: 36676959doi: 10.3390/metabo13010034google scholar: lookup
  40. Cho ES, Cha YH, Kim HS, Kim NH, Yook JI. The pentose phosphate pathway as a potential target for cancer therapy.. Biomol Ther Seoul 2018;26(1):29–38.
    pmc: PMC5746035pubmed: 29212304doi: 10.4062/biomolther.2017.179google scholar: lookup
  41. Chen C, Zhang X. Glycolysis regulator PFKP induces human melanoma cell proliferation and tumor growth.. Clin Transl Oncol 2023;25(7):2183–91.
    pubmed: 36792847doi: 10.1007/s12094-023-03096-7google scholar: lookup
  42. Ling X, Zhang L, Fang C, Liang H, Ma J. A comprehensive prognostic and immunological implications of PFKP in pan-cancer.. Cancer Cell Int 2024;24(1):310.
    pmc: PMC11385129pubmed: 39252014doi: 10.1186/s12935-024-03497-wgoogle scholar: lookup
  43. Liu T, Qi J, Wu H, Wang L, Zhu L, Qin C, Zhang J, Zhu Q. Phosphogluconate dehydrogenase is a predictive biomarker for immunotherapy in hepatocellular carcinoma.. Front Oncol 2022;12: 993503.
    pmc: PMC9632284pubmed: 36338768doi: 10.3389/fonc.2022.993503google scholar: lookup
  44. Ros S, Schulze A. Balancing glycolytic flux: the role of 6-phosphofructo-2-kinase/fructose 2, 6-bisphosphatases in cancer metabolism.. Cancer Metab 2013;1:1–10.
    pmc: PMC4178209pubmed: 24280138doi: 10.1186/2049-3002-1-8google scholar: lookup
  45. Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation.. Cells 2021;10(5):1056.
    pmc: PMC8146072pubmed: 33946927doi: 10.3390/cells10051056google scholar: lookup
  46. Koni M, Pinnaro V, Brizzi MF. The Wnt signalling pathway: a tailored target in cancer.. Int J Mol Sci 2020;21(20): 7697.
    pmc: PMC7589708pubmed: 33080952doi: 10.3390/ijms21207697google scholar: lookup
  47. Polakis P. Drugging Wnt signalling in cancer.. EMBO J 2012;31(12):2737–46.
    pmc: PMC3380214pubmed: 22617421doi: 10.1038/emboj.2012.126google scholar: lookup
  48. Goldsberry WN, Londono A, Randall TD, Norian LA, Arend RC. A review of the role of Wnt in cancer immunomodulation.. Cancers (Basel) 2019;11(6): 771.
    pmc: PMC6628296pubmed: 31167446doi: 10.3390/cancers11060771google scholar: lookup
  49. van de Schans VAM, Smits JFM, Blankesteijn WM. The Wnt/frizzled pathway in cardiovascular development and disease: friend or foe?. Eur J Pharmacol 2008;585(2–3):338–45.
    pubmed: 18417121doi: 10.1016/j.ejphar.2008.02.093google scholar: lookup
  50. Logan CY, Nusse R. The Wnt signaling pathway in development and disease.. Annu Rev Cell Dev Biol 2004;20:781–810.
    pubmed: 15473860doi: 10.1146/annurev.cellbio.20.010403.113126google scholar: lookup
  51. Suthon S, Perkins RS, Bryja V, Miranda-Carboni GA, Krum SA. WNT5B in physiology and disease.. Front Cell Dev Biol 2021;9: 667581.
    pmc: PMC8129536pubmed: 34017835doi: 10.3389/fcell.2021.667581google scholar: lookup
  52. Xue G, Romano E, Massi D, Mandala M. Wnt/beta-catenin signaling in melanoma: preclinical rationale and novel therapeutic insights.. Cancer Treat Rev 2016;49:1–12.
    pubmed: 27395773doi: 10.1016/j.ctrv.2016.06.009google scholar: lookup
  53. Chen Y, Chen Z, Tang Y, Xiao Q. The involvement of noncanonical Wnt signaling in cancers.. Biomed Pharmacother 2021;133: 110946.
    pubmed: 33212376doi: 10.1016/j.biopha.2020.110946google scholar: lookup
  54. Winter CG, Wang B, Ballew A, Royou A, Karess R, Axelrod JD, Luo L. Rho-associated kinase (Drok) links frizzled-mediated planar cell polarity signaling to the actin cytoskeleton.. Cell 2001;105(1):81–91.
    pubmed: 11301004doi: 10.1016/s0092-8674(01)00298-7google scholar: lookup
  55. Komiya Y, Habas R. Wnt signal transduction pathways.. Organogenesis 2008;4(2):68–75.
    pmc: PMC2634250pubmed: 19279717doi: 10.4161/org.4.2.5851google scholar: lookup
  56. Slusarski DC, Yang-Snyder J, Busa WB, Moon RT. Modulation of embryonic intracellular Ca signaling by Wnt-5A.. Dev Biol 1997;182(1):114–20.
    pubmed: 9073455doi: 10.1006/dbio.1996.8463google scholar: lookup
  57. Kuhl M, Sheldahl LC, Malbon CC, Moon RT. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and Frizzled homologs and promotes ventral cell fates in Xenopus.. J Biol Chem 2000;275(17):12701–11.
    pubmed: 10777564doi: 10.1074/jbc.275.17.12701google scholar: lookup
  58. Wang HY, Malbon CC. Wnt signaling, Ca, and cyclic GMP: visualizing Frizzled functions.. Science 2003;300(5625):1529–30.
    pubmed: 12791979doi: 10.1126/science.1085259google scholar: lookup
  59. Dejmek J, Safholm A, Kamp Nielsen C, Andersson T, Leandersson K. Wnt-5a/Ca-induced NFAT activity is counteracted by Wnt-5a/Yes-Cdc42-casein kinase 1alpha signaling in human mammary epithelial cells.. Mol Cell Biol 2006;26(16):6024–36.
    pmc: PMC1592795pubmed: 16880514doi: 10.1128/mcb.02354-05google scholar: lookup
  60. Toker A. The biology and biochemistry of diacylglycerol signalling. Meeting on molecular advances in diacylglycerol signalling.. EMBO Rep 2005;6(4):310–314.
    pmc: PMC1299288pubmed: 15791268doi: 10.1038/sj.embor.7400378google scholar: lookup
  61. Qin K, Yu M, Fan J, Wang H, Zhao P, Zhao G, Zeng W, Chen C, Wang Y, Wang A. Canonical and noncanonical Wnt signaling: Multilayered mediators, signaling mechanisms and major signaling crosstalk.. Genes Dis 2024;11(1):103–34.
    pmc: PMC10425814pubmed: 37588235doi: 10.1016/j.gendis.2023.01.030google scholar: lookup
  62. Krishna S, Zhong XP. Regulation of lipid signaling by diacylglycerol kinases during T cell development and function.. Front Immunol 2013;4: 178.
    pmc: PMC3701226pubmed: 23847619doi: 10.3389/fimmu.2013.00178google scholar: lookup
  63. Katoh M. WNT2B: comparative integromics and clinical applications (review).. Int J Mol Med 2005;16(6):1103–8.
    pubmed: 16273293doi: 10.3892/ijmm.16.6.1103google scholar: lookup
  64. Clevers H, Nusse R. Wnt/beta-catenin signaling and disease.. Cell 2012;149(6):1192–205.
    pubmed: 22682243doi: 10.1016/j.cell.2012.05.012google scholar: lookup
  65. Ikeda S, Kishida S, Yamamoto H, Murai H, Koyama S, Kikuchi A. Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.. EMBO J 1998;17(5):1371–84.
    pmc: PMC1170485pubmed: 9482734doi: 10.1093/emboj/17.5.1371google scholar: lookup
  66. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism.. Cell 2002;108(6):837–47.
    pubmed: 11955436doi: 10.1016/s0092-8674(02)00685-2google scholar: lookup
  67. Hurlstone A, Clevers H. T-cell factors: turn-ons and turn-offs.. EMBO J 2002;21(10):2303–11.
    pmc: PMC126013pubmed: 12006483doi: 10.1093/emboj/21.10.2303google scholar: lookup
  68. Le Floch N, Rivat C, De Wever O, Bruyneel E, Mareel M, Dale T, Gespach C. The proinvasive activity of Wnt-2 is mediated through a noncanonical Wnt pathway coupled to GSK-3β and c-Jun/AP-1 signaling.. FASEB J 2005;19(1):144–6.
    pubmed: 15507471doi: 10.1096/fj.04-2373fjegoogle scholar: lookup
  69. Jung YS, Jun S, Lee SH, Sharma A, Park JI. Wnt2 complements Wnt/beta-catenin signaling in colorectal cancer.. Oncotarget 2015;6(35):37257–37268.
    pmc: PMC4741928pubmed: 26484565doi: 10.18632/oncotarget.6133google scholar: lookup
  70. Pham K, Milovanovic T, Barr RJ, Truong T, Holcombe RF. Wnt ligand expression in malignant melanoma: pilot study indicating correlation with histopathological features.. Mol Pathol 2003;56(5):280–5.
    pmc: PMC1187339pubmed: 14514922doi: 10.1136/mp.56.5.280google scholar: lookup
  71. Anastas JN, Moon RT. Wnt signalling pathways as therapeutic targets in cancer.. Nat Rev Cancer 2013;13(1):11–26.
    pubmed: 23258168doi: 10.1038/nrc3419google scholar: lookup
  72. Nusse R, Clevers H. Wnt/beta-catenin signaling, disease, and emerging therapeutic modalities.. Cell 2017;169(6):985–99.
    pubmed: 28575679doi: 10.1016/j.cell.2017.05.016google scholar: lookup
  73. Goldsberry WN, Londono A, Randall TD, Norian LA, Arend RC. A review of the role of Wnt in cancer immunomodulation.. Cancers (Basel) .
    pmc: PMC6628296pubmed: 31167446doi: 10.3390/cancers11060771google scholar: lookup

Citations

This article has been cited 0 times.
Subscribe to our newsletter
Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.